HyBryte FLASH2 Futility Stop: Soligenix Exits CTCL With No Efficacy Data, No Salvage Path

Soligenix Halts Phase III CTCL Program for HyBryte

Soligenix has discontinued the Phase III development of its topical cutaneous T-cell lymphoma (CTCL) therapy, HyBryte (SGX301), after an interim analysis of the FLASH2 trial (NCT06470451) indicated it was unlikely to meet its primary goals. The company will now pivot its focus towards advancing dusquetide for Behçet’s disease, which has shown safety and tolerability in a Phase II study, and exploring commercial opportunities for its ambient-stable vaccine platform, ThermoVax, including candidates for Filoviral strains and Covid-19.

• HyBryte, a topical gel designed to selectively destroy malignant T-cells in CTCL lesions using visible light-activated hypericin, failed to demonstrate early signs of success in its Phase III FLASH2 trial (NCT06470451). An interim analysis by the data monitoring committee in May 2026 concluded the trial was unlikely to achieve its primary endpoints, leading Soligenix to terminate the program.
• Following the discontinuation of HyBryte, Soligenix is re-prioritizing its pipeline. The company will now focus on developing dusquetide for the rare inflammatory blood vessel condition, Behçet’s disease, building on positive safety and tolerability data from a Phase II study (NCT06386744). Additionally, Soligenix aims to commercialize its ThermoVax platform for ambient-stable vaccines, with early-stage candidates for Ebola and Covid-19.
• The decision comes amidst a CTCL treatment landscape that has seen recent advancements, including the 2017 approval of Adcetris (brentuximab vedotin), which generated $1.8 billion in 2025 sales, and the 2024 FDA approval of Lymphir (denileukin diftitox). Despite these developments, significant unmet needs persist for CTCL patients, particularly regarding delayed diagnosis and the management of chronic itch, highlighting the ongoing challenge in this rare lymphoma.

Unpacking the Phase III FLASH2 Trial Design for HyBryte

The Phase III FLASH2 trial builds on a broader landscape of CTCL clinical investigation spanning multiple therapeutic modalities and study designs. The trials below illustrate the range of endpoints and parameters used to evaluate efficacy across systemic, epigenetic, phototherapy, and topical approaches in this disease setting.

Addressing Persistent Unmet Needs in CTCL Treatment

Current treatment approaches for CTCL are constrained by a combination of limited long-term efficacy, cumulative toxicities, and inadequate symptom control — particularly in relapsed or refractory settings. Because patients rarely achieve a cure, the treatment paradigm necessitates sustained sequential therapy, placing a premium on tolerability and durability of response.

• Limited efficacy against pruritus in advanced disease: Lymphoma-directed therapies remain the primary strategy for managing CTCL-associated pruritus; however, in patients with relapsed or refractory disease experiencing severe itch, these approaches frequently provide insufficient relief. Conventional antipruritic agents have not demonstrated adequate symptom control in this population, and dedicated itch-targeted therapies remain an unmet need.

• Short duration of response with conventional chemotherapy: While systemic chemotherapies can produce rapid responses and high initial response rates, these are generally short-lived and accompanied by myelosuppression and immunosuppression. Notably, patients who received biologic response modifiers and histone deacetylase inhibitors as initial therapy demonstrated substantially better survival (2.5 years) compared to those initially treated with multiagent chemotherapy (9 months).

• Cumulative toxicity from radiotherapy: Electron beam therapy, including total skin electron beam therapy (TSEBT), has been used for decades and offers high response rates, but carries a well-established risk of cumulative skin toxicity that limits repeated use over the disease course.

• Inadequate standardization of pruritus assessment: Partly owing to a lack of validated therapeutic options, pruritus is rarely assessed in a standardized manner within routine clinical practice — despite being among the most distressing and functionally debilitating symptoms experienced by CTCL patients.

• Significant treatment resistance in advanced disease: Clinical data highlight the burden of resistance in heavily pretreated populations; patients with chemotherapy-resistant advanced peripheral T-cell lymphoma had a median of four prior lines of chemotherapy (range: 2–10), with all patients exhibiting progressive disease prior to transplantation — underscoring the critical need for more effective salvage strategies.

Beyond HyBryte: Emerging Frontiers in CTCL Therapy

Recent research has expanded the therapeutic landscape of CTCL well beyond conventional approaches, with several molecularly distinct targets under active investigation. KIR3DL2, a receptor broadly expressed on malignant CTCL cells but rarely on normal immune cells, has emerged as a compelling immunotherapeutic target. IPH4102, a humanized monoclonal antibody directed against KIR3DL2, has demonstrated potent antitumor activity through antibody-dependent cell cytotoxicity and phagocytosis in preclinical models, improving survival and reducing tumor growth in KIR3DL2(+) tumor-bearing mice while selectively eliminating primary Sézary cells. Preliminary clinical investigation of IPH4102 is now underway. Similarly, CCR4 — a skin-homing receptor predominantly expressed on Sézary cells — is targeted by mogamulizumab, an anti-CCR4 monoclonal antibody shown to improve progression-free survival. Notably, mogamulizumab's mechanism extends beyond direct Sézary cell depletion, contributing to immune reconstitution and remodeling of both malignant and benign lymphocyte subsets.

Intracellular signaling pathways represent another area of active therapeutic exploration. The JAK/STAT axis has garnered particular attention, with the combination of JAK1/2 inhibitor ruxolitinib and HDAC inhibitor resminostat demonstrating strong synergistic antitumor effects in CTCL cell lines. Romidepsin in combination with JAK inhibitors has similarly produced markedly enhanced therapeutic responses, with abrogation of JAK/STAT signaling identified as a key mechanistic mediator. In parallel, the PI3K/AKT/mTOR pathway has been shown to be hyperactivated in skin-derived Sézary syndrome cells relative to paired blood counterparts, and multiple inhibitors targeting this axis are currently under clinical evaluation. The loss of SHP-1 tumor suppressor tyrosine phosphatase — silenced through activated phosphorylated STAT3 in cooperation with DNA methyltransferase 1 (DNMT1) — represents an additional mechanistic vulnerability that correlates with advanced disease stage.

Epigenetic dysregulation continues to be a productive area of investigation, with HDAC inhibitors already approved for CTCL and ongoing research seeking to optimize their use in combination regimens. These agents modulate gene expression by increasing nuclear histone acetylation and driving chromatin remodeling, thereby influencing oncogenic transcriptional programs. Beyond established targets, recent profiling studies have identified novel surface and functional markers — including GPR15, PTPN13, KLRB1, and ITGB1 — as candidate targets with potential diagnostic and therapeutic relevance. Collectively, these advances underscore a shift toward biologically stratified, mechanism-driven treatment strategies in CTCL.